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Dysregulation of DYRK1A kinase
expression leads to disease in humans;
its overexpression is linked to Down
syndrome pathological traits, and its
haploinsufficiency causes a clinical
syndrome. Rozen et al. show that normal
levels of DYRK1A are required for
physiological angiogenesis, acting
positively on VEGF-dependent NFAT
transcription in endothelial cells.
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Angiogenesis is a highly regulated process essential
for organ development and maintenance, and its
deregulation contributes to inflammation, cardiac
disorders, and cancer. The Ca2+/nuclear factor of
activated T cells (NFAT) signaling pathway is central
to endothelial cell angiogenic responses, and it is
activated by stimuli like vascular endothelial growth
factor (VEGF) A. NFAT phosphorylation by dual-
specificity tyrosine phosphorylation-regulated ki-
nases (DYRKs) is thought to be an inactivating event.
Contrary to expectations, we show that the DYRK
family member DYRK1A positively regulates VEGF-
dependent NFAT transcriptional responses in pri-
mary endothelial cells. DYRK1A silencing reduces
intracellular Ca2+ influx in response to VEGF, which
dampens NFAT activation. The effect is exerted at
the level of VEGFR2 accumulation leading to impair-
ment in PLCg1 activation. Notably, Dyrk1a heterozy-
gous mice show defects in developmental retinal
vascularization. Our data establish a regulatory cir-
cuit, DYRK1A/ Ca2+/NFAT, to fine-tune endothelial
cell proliferation and angiogenesis.
INTRODUCTION
Vascular endothelial growth factor (VEGF) is the principal regulator
of new blood vessel sprouting, promoting a range of cellular re-
sponses in endothelial cells (ECs) that include survival, prolifera-
tion, migration, invasion, and/or permeability (reviewed in Herbert
and Stainier, 2011). VEGF exerts its effects by activating its
cognate tyrosine kinase receptor, VEGFR (encoded by the KDR,Ce
This is an open access article under the CC BY-NFLT1, andFLT4genes),which thereafterengagesmultiple intracel-
lular signaling cascades that include the extracellular regulated
kinase/mitogen-activated protein kinases (ERK/MAPKs), the
phosphoinositide 3-kinase (PI3K)/AKT pathway, or the phospholi-
pase Cg (PLCg)/Ca2+ pathway (reviewed in Simons et al., 2016).
The PLCg/Ca2+ pathway is responsible for the opening of the
Ca2+ channel receptors in the endoplasmic reticulum (ER) mem-
brane and the subsequent opening ofCa2+ channels in the plasma
membrane that leads to an increase in intracellular Ca2+ (reviewed
in Soboloff et al., 2012). This event activates the phosphatase cal-
cineurin (CN), which leads to the dephosphorylation of the nuclear
factor of activated T cells (NFAT) family of transcription factors and
its relocalization to the nucleus,where it regulates the transcription
of target genes central to angiogenesis (reviewed in M€uller and
Rao, 2010). A number of kinases are known tomodulate NFAT ac-
tivity and subcellular localization, producing both positive and
inhibitory outcomes. The first group includes the MAPK, JNK, or
vaccinia-related kinase 2, while negative regulatory kinases
include protein kinase A, glycogen synthase kinase 3 (GSK3),
casein kinase 1 (CK1), and members of the dual specificity tyro-
sine-regulatedkinase (DYRK) family (reviewed inShouetal., 2015).
DYRKs are an evolutionarily conserved family of kinases
belonging to the CMGC group that participate in signaling path-
ways that are critical for development and in maintaining cell
homeostasis (reviewed in Aranda et al., 2011). There are
five members of the mammalian DYRK subfamily (DYRK1A,
DYRK1B, DYRK2, DYRK3, and DYRK4) that have distinct
expression patterns and, to some extent, different substrate
specificity. DYRK1A is the best-studied member of the family
due to its link to human pathologies, both when overexpressed
as part of the Down syndrome critical region (reviewed in Park
and Chung, 2013) or when in haploinsufficiency associated to
a complex clinical syndrome (Bronicki et al., 2015). Human
DYRK1A and DYRK2 interact with and phosphorylate the regula-





Figure 1. Downregulation of DYRK1A
Impairs the Expression of VEGF-Induced
NFAT Target Genes
(A) Schematic representation of the main signaling
pathways activated by VEGF.
(B) Genes regulated significantly by VEGF were
classified as VEGF up- or downregulated genes
(1.4 > FC > 1.4, p < 0.05) and further subdivided
in function of the effect of CsA as CsA-inhibited
(CsA Down; FC < 1.3, p < 0.05), CsA-unchanged
(CsA n/c) and CsA-enhanced genes (CsA Up,
FC > 1.3, p < 0.05). See also Figure S2 for further
analysis.
(C) Cluster analysis of VEGF-upregulated and
CsA-inhibited genes. The color key refers to
‘‘normalized intensity’’ of the microarray data.
(D–F) Boxplots representing the median expres-
sion of all the genes in CsA-inhibited (D), Csa-un-
changed (E), and CsA-enhanced (F) categories:
basal (white), VEGF induced (light gray), and VEGF
induced + CsA (dark gray). Center lines show the
medians, box limits indicate the 25th and 75th
percentiles, whiskers extend 1.5 times the inter-
quartile range from the 25th and 75th percentiles,
and outliers are represented by dots (2-way
ANOVA with Bonferroni correction for multiple
comparisons).
(G and H) Expression of selected genes in the
shControl or shDYRK1A-infected HUVECs deter-
mined by qRT-PCR in the VEGF up/CsA inhibited
group (G) or in the other two groups (H). Data
are relative to the induction following VEGF stim-
ulation in shControl cells set arbitrarily as 1
(mean ± SD; n = 3, assayed in triplicate; pairwise
comparisons with a two-tailed Mann-Whitney
U test; see also Figure S2).GSK3 phosphorylation (Arron et al., 2006; Gwack et al., 2006).
DYRK1A and DYRK3 have also been proposed to repress
NFAT transcriptional activity in different experimental models
of overexpression in the context of pathophysiological NFAT
activation such as cardiac hypertrophy, osteoclast differentia-
tion, or pancreatic beta cell replication (Bogacheva et al., 2008;
Grebe et al., 2011; Lee et al., 2009; Wang et al., 2015).
Here, we set out to characterize whether DYRKs regulate
VEGF-induced Ca2+/NFAT signaling in ECs, focusing on
DYRK1A. In contrast to what was expected, we found that
DYRK1A was required for the correct activation of NFAT upon
VEGF stimulation. Downregulation of DYRK1A resulted in less
EC proliferation and reduced angiogenesis in vitro. In agreement,
heterozygous Dyrk1a mice responded poorly in ex vivo angio-
genesis assays and show altered developmental angiogenesis
during retinal vasculogenesis. Mechanistically, we show that
DYRK1A acts upstream of the increase in intracellular Ca2+
induced by VEGF at the level of receptor accumulation.
RESULTS
DYRK1A Is Required for Correct Activation of the Ca2+/
NFAT Signaling Pathway by VEGF
Phosphorylation of NFAT proteins by DYRK1A and DYRK2 has
been shown to be an inactivating event (Arron et al., 2006; Gwack1868 Cell Reports 23, 1867–1878, May 8, 2018et al., 2006). Given that NFATs are key downstream effectors of
VEGF (Figure 1A), we asked whether DYRK1A might affect tran-
scriptional responses to VEGF-A (hereinafter VEGF) in primary
ECs. To this end, RNA microarray analysis was performed using
VEGF-stimulated human umbilical vein ECs (HUVECs) infected
with a lentivirus expressing a control small hairpin RNA (shRNA)
or an shRNA targeting DYRK1A (Figures S1A and S1B). The
silencingofDYRK1Adidnot affect theexpressionof otherDYRKs
(Figure S1C), ruling out possible compensatory effects. In addi-
tion, as a validation of the experimental setup, the microarray re-
sults from noninfected HUVECs were compared with those from
shControl-infected ones, demonstrating a large overlap in the
VEGF upregulated genes (Figure S1D) and indicating that lentivi-
ral infection per se did not drastically affect the ability of VEGF to
induce its transcriptional program.
We focused on those genes induced 1 hr after VEGF stimula-
tion because they are more likely to represent primary transcrip-
tional targets. To discriminate the NFAT-dependent group of
genes, we also analyzed VEGF-stimulated cells in the presence
of the CN/NFAT inhibitor cyclosporin A (CsA) (Figures S1A and
S1B). Analysis of the microarray data showed that 188 genes
were significantly upregulated by VEGF in control cells, while
45 genes were downregulated by such stimulation (Figure 1B).
Indeed, the data were concordant with earlier expression




Figure 2. DYRK1A Is Required for NFAT-
Dependent Transcriptional Activation
(A) Induction profile of several NFAT-dependent
genes analyzed by qRT-PCR in HUVECs stimu-
lated with VEGF; a treatment with CsA is also
included. Values of untreated shControl cells were
arbitrarily set as 1, and the data correspond to one
representative experiment (mean ± SD; DYRK1A
knockdown levels are shown in Figure S3A).
(B) Luciferase reporter assays performed in
shControl and shDYRK1A cells transiently trans-
fected with a NFAT reporter plasmid (see scheme).
The cells were left untreated (basal) or stimulated
with VEGF for 6 hr, and the values for the basal
condition were set as 1 (mean ± SD of transfection
triplicates). DYRK1A knockdownwas assessed by
qRT-PCR in parallel samples.
(C) Analysis of NFAT proteins in HUVECs stimu-
lated with VEGF. NFAT-hyperphosphorylation
was induced by CsA treatment (the brackets
indicate the dephosphorylated species). RCAN1 is
included as a readout of NFAT activation.
(D and E) Nuclear translocation of a GFP-NFAT
fusion protein in shControl and shDYRK1A in-
fected HUVECs (DYRK1A knockdown levels in
Figure S3F) induced by VEGF stimulation. Repre-
sentative images of each condition (D; scale bar,
25 mm) and quantification of cells expressing nu-
clear GFP-NFAT (E; 100 cells were counted for
each condition; mean ± SD).2004; Schweighofer et al., 2009). Three groups of genes induced
by VEGF were distinguished: genes whose expression did not
change significantly in the presence of CsA, genes that were
further induced by CsA, and genes whose induction was
reduced more than 30% by CsA (Figures 1B–1F; see also Fig-
ure S1E). This latter group defines the genes that require NFAT
activation for their expression to be induced by VEGF, and it in-
cludes already known targets of NFAT such asRCAN1.4 (Minami
et al., 2004; Yang et al., 2000) and other genes that are induced
by NFATc1 overexpression or that have NFATc1 occupancy at
their proximal promoter regions in HUVECs (Suehiro et al.,
2014). When we compared the behavior of these three groups
of genes in control cells and DYRK1A-silenced cells, significant
changes in VEGF-dependent induction were only observed for
the group of genes inhibited by CsA, the activation of which
was dampened in the absence of DYRK1A (Figures 1D–1F).
qRT-PCR analysis validated the microarray data (Figures 1G
and 1H; see also Figure S2) and confirmed that only the genes
inhibited by CsA displayed a lower induction in response to
VEGF when DYRK1A was silenced.
DYRK1A Depletion Dampens VEGF-Induced NFAT-
Dependent Transcriptional Responses
We reasoned that the weaker induction of NFAT targets in
DYRK1A silenced cells could be due to a delayed response
rather than to reduced transcription. The temporal pattern ofCellinduction was very similar in shDYRK1A
cells compared to control cells, but the
mRNA levels were reduced at each timepoint analyzed (Figure 2A; see also Figures S3B and S3C for a
parallel assessment of RCAN1 mRNA and protein), ruling out a
delay in transcriptional activation. We next assessed NFAT tran-
scriptional activity more directly by analyzing the activity of a
luciferase reporter under the control of theRCAN1.4 internal pro-
moter, which is known to depend on NFAT activity (Minami et al.,
2004). Whereas reporter activity was induced by VEGF in control
cells, little activation was observed in cells silenced for DYRK1A
(Figure 2B for shRNA treatment and Figure S3D for siRNA),
further confirming that the depletion of endogenous DYRK1A
impairs VEGF-dependent NFAT activation.
NFAT activation by VEGF requires the dephosphorylation of
the NFAT proteins, which can be traced by the appearance of
faster-migrating electrophoretic bands sensitive to CN inhibition
(CsA treatment) (Figure 2C). An effect of DYRK1A phosphoryla-
tion on NFATc1 stability has been reported (Liu et al., 2017),
but DYRK1A depletion did not affect NFAT protein accumulation
in this cellular context (Figure S3E). However, a reduction was
detected in the NFAT protein isoforms with increased electro-
phoretic mobility, which likely corresponds to the hypophos-
phorylated forms (Figure 2C). The result is quite surprising given
that DYRK1A has been shown to directly phosphorylate NFATs
(Arron et al., 2006; Gwack et al., 2006), and hence, an increase
in the hypophosphorylated forms when DYRK1A is reduced
would be expected. Changes in NFATs phosphorylation are
directly responsible of their nucleocytoplasmic transport, withReports 23, 1867–1878, May 8, 2018 1869
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Figure 3. DYRK1A Kinase Activity Is Neces-
sary for NFAT Signaling
(A) Expression of selected genes determined by
qRT-PCR in control cells and in cells over-
expressing DYRK1A. The induction in control cells
after VEGF stimulation was set as 1 (mean ± SD;
n = 3 independent experiments; see also Figures
S4A and S4B).
(B) RCAN1.4mRNA expression upon VEGF stimu-
lation in cells expressing a control shRNA, a shRNA
against the 30 UTR of DYRK1A (#3), or in cells co-
expressing the shRNAs indicated and a shRNA-
resistant DYRK1A (mean ± SD of PCR triplicates
in a representative experiment). The changes in
DYRK1A were analyzed in western blots (top).
(C) VEGF-dependent induction of NFAT target
genes in HUVECs treated for 6 hr with vehicle
(DMSO) or harmine (the level of induction in
HUVECs stimulated with VEGF in the presence of
DMSO was set as 1; mean ± SD of PCR triplicates
in a representative experiment; see also Figures
S4G and S4H).
(D) Western blot analysis of HUVECs infected with
the indicated lentiviruses and stimulated with
VEGF in the presence of the vehicle alone or
harmine.dephosphorylated NFATs entering the nucleus upon signaling as
illustrated by the nuclear accumulation of a GFP-NFAT fusion
protein upon VEGF stimulation (Figure 2D). However, GFP-
NFAT nuclear localization was impaired in DYRK1A-silenced
cells (Figures 2D and 2E), a result that agrees with the increase
in NFAT phosphorylation detected in the immunoblots.
Together, these results define an unexpected yet critical role
for DYRK1A in the VEGF-induced dephosphorylation of NFAT
and its subsequent transcriptional activation.
The Effect of DYRK1A on VEGF Responses Depends on
Its Catalytic Activity
DYRK1A overexpression appears to inhibit NFAT activation in
different physiological contexts (Arron et al., 2006; Grebe et al.,
2011; Gwack et al., 2006; Lee et al., 2009). We assessed this ef-
fect in our experimental system. In this case, the effect on the
activation of NFAT targets was highly variable from experiment
to experiment (Figure 3A); only high levels of DYRK1A dampened
VEGF-dependent activation of NFAT targets (Figure S4A), while
lower levels did alter neither NFAT phosphorylation nor NFAT
target expression (Figures S4A and S4B). In addition, unlike
endogenous DYRK1A, which was detected mostly in the cytosol
of HUVECs, exogenously expressed DYRK1A accumulated
almost exclusively in the nucleus (Figure S4C). It is therefore
possible that high levels of exogenously expressed nuclear
DYRK1A would drive the phosphorylation of endogenous
NFAT and subsequent transcriptional inhibition.
DYRK1A re-expression restored the induction levels of the
NFAT target RCAN1.4 (Figure 3B), and other NFAT targets
were partially rescued (Figure S4D). These results argue against
off-target effects and clearly establish a dependence on
DYRK1A expression. DYRK1A is catalytically active in HUVECs
upon VEGF stimulation (Figures S4E and S4F), and thus, we
wondered whether the kinase activity is required for DYRK1A-1870 Cell Reports 23, 1867–1878, May 8, 2018mediated effects. Unfortunately, we could not get detectable
expression of a DYRK1A kinase inactive mutant in HUVECs to
evaluate kinase-dependency. As an alternative, prior to VEGF
stimulation we exposed HUVECs to harmine, a known inhibitor
of DYRK1A kinase activity (Bain et al., 2007; Laguna et al.,
2008). Harmine treatmentmimicked the effect of DYRK1A down-
regulation, as the VEGF-dependent induction of NFAT targets
was dampened in harmine-treated cells (Figure 3C), an effect
that was enhanced as the pretreatment time increased (Figures
S4G and S4H). Moreover, the rescue achieved by DYRK1A re-
expression did not occur in the presence of harmine (Figure 3D),
confirming that NFAT’s ability to induce RCAN1.4 expression is
dependent on DYRK1A kinase activity. Notably, harmine pos-
sesses anti-angiogenic activity, as it impedes HUVEC prolifera-
tion and tube formation (Dai et al., 2012; Hamsa and Kuttan,
2010), which our results suggest could be due, at least in part,
to DYRK1A inhibition. Thus, our data suggest that the kinase
activity of DYRK1A is required to modulate VEGF/Ca2+/NFAT
signaling in HUVECs.
DYRK1A Modulates a Signaling Step in VEGF
Stimulation Upstream of the Release of Ca2+ from
Intracellular Stores
In ECs, several pro-angiogenic genes, including RCAN1.4, are
also induced by interleukin-1b (IL-1b) signaling (Schweighofer
et al., 2009). Based on our results, the induction of RCAN1.4
by IL-1b appears to be independent of NFAT activation, as it is
not affected by CsA (Figures S5A–S5C). In addition, no effect
was observed on the ability of IL-1b to induce RCAN1.4 in
DYRK1A-silenced cells, nor were other common targets of
IL-1b and VEGF signaling affected (Figures S5B and S5D). Alto-
gether, these data suggest that the signaling impairment in the
activation of pro-angiogenic genes due to DYRK1A downregula-
tion in HUVECs is restricted to the Ca2+/NFAT pathway.
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Figure 4. DYRK1A Depletion Results in
Impaired Ca2+ Mobilization upon VEGF
Stimulation
HUVECs infected with shControl or shDYRK1A
lentiviruses were growth factor deprived for 6 hr,
and intracellular Ca2+ mobilization was assayed
in vivo.
(A) Cells were treated with VEGF in isotonic solu-
tion + 1.2 mM Ca2+ (mean ± SEM, shControl,
n = 45; shDYRK1A, n = 54; p < 0.0001).
(B) Cells were treated with VEGF in a Ca2+-free
isotonic solution (0 Ca2+) and then switched to
isotonic solution + Ca2+ (mean ± SEM, shControl,
n = 113; shDRYK1A, n = 112; p < 0.0001).
(C) Cells were treated with TG in a Ca2+-free
isotonic solution (0 Ca2+) and then switched to
isotonic solution + Ca2+ (mean ± SEM, shControl,
n = 39; shDYRK1A, n = 41; p > 0.5).
(D) Cells were treated with ATP in a Ca2+-free
isotonic solution (0 Ca2+) and then switched to
isotonic solution + Ca2+( mean ± SEM, shControl,
n = 79; shDYRK1A, n = 65; p > 0.5).Next, we asked at which level of the VEGF/Ca2+/NFAT
pathway DYRK1A is acting. Based on the changes in NFAT
phosphorylation, we wondered whether DYRK1A was placed
upstream or at the level of CN activation. To evaluate this possi-
bility, we interrogated the pathway when pharmacologically
activated: the combination of ionomycin (Io), which allows the
passage of Ca2+ across membranes, and the protein kinase C
agonist phorbol 12-myristate 13-acetate (PMA) induces potent
NFAT signaling (Figure S5E). Indeed, HUVECs respond by aug-
menting RCAN1.4 transcription, and notably, DYRK1A downre-
gulation did not affect this induction (Figures S5G and S5H).
Importantly, the fact that the effects of DYRK1A downregulation
on NFAT signaling are overridden when Ca2+ freely enters the
cell suggests that DYRK1A must act upstream of cytosolic
Ca2+ release.
To test this hypothesis, we analyzed howdepletion of DYRK1A
affected intracellular Ca2+ mobilization, and we found a strong
reduction in cytosolic Ca2+ signals in response to VEGF in
shDYRK1A-infected cells compared to control cells (Figure 4A).
The different components of cytosolic Ca2+ signals recorded in
response to VEGF were also evaluated with a Ca2+ add-back
protocol (Figure 4B). While the first peak, corresponding to
Ca2+ release from intracellular stores (mainly the ER), was clearly
reduced in DYRK1A-silenced HUVECs, the entry component
following Ca2+ addition was unaltered (Figure 4B). To distinguish
whether DYRK1A participates in controlling Ca2+ accumulation
in the ER or VEGF-mediated Ca2+ release from the ER, we
used the sarco/ER Ca2+-ATPase pump inhibitor thapsigargin
(TG). The ability of TG to empty the intracellular stores and the
subsequent activation of store-operated Ca2+ entry were not
different in shControl and shDYRK1A-expressing cells (Fig-
ure 4C); in addition, no defects were observed when Ca2+ entry
was induced with a Ca2+ mobilizer as ATP or with ionophore
treatment (Figures 4D and S5F). Together, these results indicatethat the lack of DYRK1A prevents Ca2+ release from the ER inter-
fering at an upstream signaling step.
DYRK1A-DependentModulation of Ca2+/NFAT Signaling
Is Mediated at the Level of VEGFR2 Stability
The release of Ca2+ from the ER is triggered by the ligand-bound
receptor signaling events that lead to the activation of PLCg. We
have previously reported that DYRK1A controls the availability of
RTK (EGF receptor) by regulating its half-life (Ferron et al., 2010).
Therefore, in a search for the molecular mechanism explaining
how DYRK1A might regulate Ca2+/NFAT signaling, we tested
whether VEGF receptor (VEGFR2) accumulation was affected
by DYRK1A downregulation. As other RTKs, VEGFR2 undergoes
endocytosis and subsequent targeting for either recycling or
degradation upon ligand binding (reviewed in Simons et al.,
2016). Our results showed that VEGFR2 accumulation in
response to VEGF was reduced in cells depleted of DYRK1A
(Figures 5A and 5B). Concomitant with this reduction, the phos-
phorylation levels of several of the tyrosine residues involved in
VEGFR2-dependent signaling cascades were also reduced (Fig-
ures 5A and 5B; see also Figures S6A and S6B). The decrease
paralleled VEGFR2 amounts, since the ratio pY1175/total was
not significantly different (Figure 5D). In particular, phosphory-
lated Y1175 in VEGFR2 is the docking site for PLCg1, and it is
crucial to initiate PLCg1/Ca2+ signaling. Accordingly, the reduc-
tion in VEGFR2-pY1175 resulted in decreased PLCg1 activation
as measured by reduced Y783 phosphorylation (Figure 5D).
Likewise, the activation of downstream signaling pathways
was also negatively affected by silencing DYRK1A (Figure 5D).
Notably, no changes in VEGFR2 mRNA were detected in
DYRK1A-silenced cells (Figure 5C), indicating that the effect on
VEGFR2 accumulation was post-transcriptional. Indeed, degra-
dation of VEGFR2 in cells treated with the protein synthesis
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Figure 5. DYRK1A’s Effect on Ca2+/NFAT Signaling Is Exerted at the Level of VEGFR2 Accumulation
(A andB) Immunoblot analysis to track the activation of VEGFR2 and downstream effectors. A representative image (A; C refers to normal growing conditions) and
the relative quantification of the signals for VEGFR2 and VEGFR2 phosphorylated at Y1175 (B) with respect to the values in shControl cells at t = 0 (total) or
t = 10 min (for pY1175) set arbitrarily as 1 (mean ± SD; n = 10; see also Figures S6A and S6B).
(C) VEGFR2 andDYRK1AmRNA levels in HUVECs treatedwith VEGF. The values in shControl cells at t = 0were set up as 1 (mean ±SD; n = 2; see also Figure S6C
for quantification of cells growing in normal conditions).
(D) Activation of the effectors indicated represented as the ratio of the signals for the phospho-antibodies to the pan-antibodies; the values in shControl cells at
t = 10 min were set arbitrarily as 1 (mean ± SD; pVEGFR2/VEGFR2, n = 10; pPLCg1/PLCg1, n = 4; pERK/ERK, n = 4; pAKT/AKT, n = 3; 2-way ANOVA with
(legend continued on next page)
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cells (Figure 5E), suggesting a higher turnover rate in the absence
of DYRK1A. This conclusion is further supported by the fact that
the reduced accumulation of VEGFR2 upon VEGF treatment
is rescued in the presence of the proteasome inhibitor
MG132 and, partially, in cells depleted of DYRK1A (Figures 5F
and 5G). Cell-surface levels of VEGFR2 were also reduced in
shDYRK1A knockdown cells (Figures 5H and 5I), which could
be a reflection of the reduction in total VEGFR2. However,
VEGF treatment induced depletion of cell-surface VEGFR2 simi-
larly in both conditions (Figures 5H and 5I), indicating that recep-
tor internalization is active in the absence of DYRK1A. To provide
further support, we used an ‘‘antibody feeding’’ assay (Gampel
et al., 2006). VEGFR2 molecules exposed in the plasma mem-
brane were labeled with a VEGFR2 extracellular-domain-spe-
cific antibody; the signals detected in cells fixed directly after
this labeling period correspond to the retention of VEGFR2 at
the cell surface (in green in Figure 5J), while the signals detected
in cells fixed and permeabilized correspond to internalized
VEGFR2 in unstimulated conditions (in red in Figure 5J) and
located in the endosomal compartment as previously described
(Gampel et al., 2006). Antibody-labeled cells were chased in vivo
for 40 min with VEGF, which induced an increase in VEGFR2
internalized in control cells consistent with ligand-induced re-
ceptor internalization (Figures 5J and S6E). In DYRK1A-silenced
cells, although VEGFR2 was internalized in both unstimulated
cells and upon VEGF treatment, the increase in the amount of
VEGFR internalized was not observed (Figure 5J; see also Fig-
ure S6E for quantifications), an effect compatible with increased
degradation of the internalized receptor.
We conclude that the reduction in VEGFR2 amounts when
DYRK1A is silenced could lead to a reduction in PLCg1 activa-
tion, which in turn would be responsible of the defects observed
in intracellular Ca2+ mobilization.
DYRK1A Is a Critical Modulator of Angiogenesis
Adequate activation of the Ca2+/NFAT pathway in response to
VEGF is required for many steps in the angiogenic process. To
test the importance of DYRK1A in this context, we first evaluated
the proliferative response of ECs upon DYRK1A downregulation.
The increase in cell number provoked by VEGF in shControl sam-
ples was not evident in shDYRK1A cells (Figure 6A). In addition,
we analyzed HUVEC behavior in Matrigel assays to follow their
ability to organize themselves in networks, a model where theBonferroni correction for multiple comparisons; the comparison between shCo
comparisons with non-parametric tests).
(E) Quantification of VEGFR2 in cells incubated with cycloheximide for 30 min
conditions (t = 0) is set as 1 (mean ± SD; n = 5).
(F and G) HUVECs infected with shControl and shDYRK1A lentiviruses were incub
cycloheximide for 30 min before VEGF treatment. When indicated, the cells were
correspond to a representative experiment (F), and the graph (G) is the quantific
(H) Localization of VEGFR2 at the cell surface as determined by immunofluoresc
untreated cells (basal) and after 40 min of VEGF treatment. Nuclei are shown in
(I) For quantification of cell-surface VEGFR2, the values are expressed in arbitrary
shControl cells in basal conditions (mean ± SD; n = 100–150 cells per each conditi
quantification in cells growing in normal conditions).
(J) Endocytosis of VEGFR2 visualized by an antibody-feeding assay in serum-star
the cell surface is determined in cells fixed (green), whereas detection of internaliz
blue (scale bar, 100 mm). See Figure S6E for quantification.CN/NFAT pathway is known to play a critical role (Rafiee
et al., 2004). In agreement with the reduced NFAT response,
DYRK1A-depleted cells were virtually unable to organize into
cord-like structures in vitro, and the effect was largely rescued
upon the re-establishment of DYRK1A expression (Figure 6B).
Next, we wanted to assess the impact of DYRK1A activity on
angiogenesis in a more physiological manner. Since Dyrk1a loss
of function is embryonic lethal inmice (Fotaki et al., 2002), we use
heterozygous mice, keeping in mind that DYRK1A haploinsuffi-
ciency is pathological in humans. First, we analyzed how mouse
lung ECs (mLECs) obtained from Dyrk1a+/ mice responded to
VEGF treatment regarding NFAT-response and found that het-
erozygous cells were unable to induce Rcan1.4 expression (Fig-
ure S7A); in agreement with the data obtained in HUVECs,
VEGFR2 protein levels were reduced in the Dyrk1a+/mLEC cul-
tures (Figure S7B). Next, we performed an ex vivo aortic ring
angiogenesis assay after checking to confirm that DYRK1A is
expressed in aortic tissue and reduced in Dyrk1a+/ mice (Fig-
ure 7A) and that it is detected in aortic ECs (Figure S7C). In accor-
dance with the DYRK1A depletion in vitro assays, vessel sprout-
ing was markedly reduced in Dyrk1a+/ aortic rings compared to
wild-type (Figure 7B; see also Figure S7D), supporting the need
for DYRK1A for a full angiogenic response in this model of
neoangiogenesis.
The role of DYRK1A was also examined in postnatal retinal
angiogenesis, a process that is driven primarily by VEGF. At
postnatal day 6 (P6), when the growing vasculature has not yet
reached the periphery of the retina, Dyrk1a heterozygous retinas
showed a reduction in the expansion of the vasculature (Figures
7C and 7D). Interestingly, the number of main vessels was signif-
icantly reduced inDyrk1a+/mice at P6 compared with wild-type
littermates (Figures 7E and S7E), with no major differences in
NG2 staining. No differences were observed in the number of
sprouts or in the branching points when the two genotypes
were compared (Figures 7F and 7G). By P11, vascular sprouts
have already invaded deep retina layers in wild-type retinas,
and the vascular plexus has undergone significant remodeling
(Figures 7H and 7I). In contrast, Dyrk1a+/ retinas showed an
immature vascular plexus; the sprouting front had not even
reached the periphery of the retina (Figure 7H), and the interme-
diate vascular plexus not even formed (Figure 7I).
The Dyrk1a loss-of-function mouse model is not endothelial
specific, and it is known that other cell types, such as retinalntrol and shDYRK1A for ERK and AKT is statistically significant in pairwise
and stimulated with VEGF for the indicated times. The protein level in basal
ated in basal medium for 6 hr in the presence of the protein synthesis inhibitor
also incubated in the presence of the proteasome inhibitor MG132. The blots
ation of 4 independent experiments (mean ± SD).
ence with an antibody against the extracellular domain of VEGFR2 (green) in
blue (scale bar, 100 mm).
units (integrated intensity of the area in each cell) and referred to the values in
on from 2 independent experiments; one-way ANOVA). See also Figure S6D for
ved cells or in cells stimulated for 40 min with VEGF. Localization of VEGFR2 at
ed VEGFR2was done in cells fixed and permeabilized (red). Nuclei are shown in
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Figure 6. DYRK1A Is Required for the Angiogenic Response of ECs
(A) Cell growth curves of HUVECs not infected (red), infected with shControl (black), or shDYRK1A (gray) plated in response to VEGF (plating day is 0; mean ± SD;
n = 2 independent experiments performed in triplicate). The level of DYRK1A depletion was assessed by western blot (see also Figure S6F for growth in the
absence of VEGF).
(B) shControl and shDYRK1A-infected HUVECs were re-infected with a control lentivirus or a lentivirus expressing DYRK1A and analyzed in 2D Matrigel assays.
Scale bar, 100 mm. (DYRK1A levels are shown in Figure S6G; see also Figures S6H–S6J for results with independent shRNAs to DYRK1A).astrocytes, play an important role in the development of the
mammalian retinal vasculature (Watanabe and Raff, 1988).
DYRK1A is expressed in all neural cell types in the developing
retina, including astrocytes (Laguna et al., 2008); therefore, it is
possible that the observed phenotype is the result of defects
not only in ECs but also in astrocytes. The analysis of the astro-
cytic network at P5 using PDGFRa as marker showed that
whereas the vascular expansion was already affected at this
postnatal age (as assessed bymeasuring IB4 staining), no differ-
ences were observed in the expansion of the astrocyte front
when Dyrk1a+/ retinas were compared to wild-type retinas (Fig-
ures S7F and S7G). Thus, although we cannot rule out that a
combination of endothelial and nonendothelial effects could
contribute to the phenotypic differences between Dyrk1a+/+
and Dyrk1a+/ mice, we think that altogether, the data support
a role for DYRK1A in physiological angiogenesis.
DISCUSSION
In the present study, we found that downregulation of DYRK1A
kinase and inhibition of its activity severely affect VEGF-depen-
dent signaling in ECs and their homeostasis. The in vitro effects
have a relevant correlation in vivo, sincewe showa strong impact
in physiological angiogenesis in a Dyrk1a haploinsufficiency
model. Furthermore, we reveal an unexpected role for DYRK1A
as a positive regulator of VEGF-dependent NFAT activation in
ECs. Indeed, our results indicate that endogenous DYRK1A is
required for the appropriate mobilization of Ca2+ from intracel-
lular stores in response to VEGF, given that DYRK1A depletion
reduces the Ca2+ spike resulting from ER Ca2+ release without
affecting extracellular Ca2+ influx; our data are compatible with
this effect being the result of the DYRK1A-dependent control
of VEGFR2 accumulation and downstream PLCg1 activation.
Transcriptional profiling of VEGF-stimulated HUVECs showed
that only a particular subset of the genes induced (those
repressed by CsA) was sensitive to DYRK1A downregulation.
The fact that NFAT proteins showed reduced dephosphorylation
and nuclear translocation following VEGF treatment in DYRK1A-1874 Cell Reports 23, 1867–1878, May 8, 2018depleted cells has allowed us to establish a molecular link be-
tween the smaller increase in intracellular Ca2+ and the reduced
NFAT-dependent transcriptional activation. This positive role for
DYRK1A in NFAT signaling is quite unexpected given its
accepted role as an inhibitory NFAT kinase (Arron et al., 2006;
Gwack et al., 2006; Kuhn et al., 2009; Lee et al., 2009; Stefos
et al., 2013). Several explanations may account for the apparent
discrepancy. First, most functional associations reported previ-
ously are based on DYRK1A overexpression. Our analysis in
different cellular systems indicates that ectopically expressed
DYRK1A accumulates in the nucleus (Alvarez et al., 2003), while
it is mostly cytosolic in endogenous conditions, as we show here
for HUVECs. It is therefore possible that strong overexpression
might favor nuclear interactions that do not necessarily take
place in physiological conditions. In fact, we only observe the in-
hibition of VEGF/NFAT targets when DYRK1A is strongly overex-
pressed, possibly indicating that such inhibition relies on
increased NFAT phosphorylation in the nucleus as shown by
others (Arron et al., 2006; Gwack et al., 2006). Second, the con-
ditions used for NFAT activation, such as constitutively active CN
or TG, override the physiological activation of the pathway and
render it independent of the step defined here. Third, the effect
of DYRK1A on NFAT activation might depend on the cellular
context and/or stimulus. Hence, the functional interaction of
DYRK1A with distinct sets of positive and/or negative regulators
within the signaling cascades could have distinct biological con-
sequences. This might explain why the DYRK inhibitor harmine
potentiates RANKL-induced NFAT activation in RAW264.7 cells
(Egusa et al., 2011), whereas we show here that it inhibits NFAT
activation by VEGF in HUVECs. Noteworthy, DYRK1A is a highly
dosage-sensitive kinase, and although some of the phenotypes
associated with DYRK1A deregulation are linear in terms of
dosage (Laguna et al., 2008), the same phenotypic output has
also been observed with both its overexpression and downregu-
lation in certain paradigms (Chen et al., 2013).
From the mechanistic point of view, our results suggest that
DYRK1A’s effect on VEGF signaling is exerted at the level of







Figure 7. Dyrk1a Heterozygous Mice Show Defects in Angiogenic Responses
(A) DYRK1A expression in aortic extracts from wild-type and Dyrk1a+/ mice analyzed by western blot.
(B) Aortic ring assays fromDyrk1a+/ female mice or their wild-type littermates performed in 2% FCSwithout (basal) or with VEGF, or in complete growth medium
(Complete). A representative picture of each condition is shown (scale bar, 0.2 mm; see also Figure S7D).
(C) Visualization of the vasculature by isolectin B4 immunofluorescence (EC membrane) and NG2 staining (pericytes) in retinas from wild-type and Dyrk1a+/
mice at P6.
(D–G) Quantification of several features of the retinal vasculature at P6 in Dyrk1a+/+ and Dyrk1a+/ animals; radial expansion (D; n = 5 for each genotype), number
of main vessels (E; +/+, n = 5; +/, n = 4; see also Figure S7E for representative images), number of sprouts (F; n = 5 for each genotype), and branch points
(G; n = 5 for each genotype) (mean ± SEM).
(H) Visualization of the vasculature by IB4 and NG2 staining in retinas from wild-type and Dyrk1a+/ mice at P11.
(I) Transversal view of CD31 stained retinas at P6 and P11 obtained by 3D reconstruction of z-projection of confocal images covering thewhole thickness of retinal
vasculature, showing the formation of the deep an intermediate plexus in wild-type and Dyrk1a+/ mice.
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at the cell surface. This results in a reduction in PLCg1 activation,
likely due to the diminished presence of VEGFR2-pY1175 mole-
cules. Reduced PLCg1 activation would affect Ca2+ mobiliza-
tion, which would ultimately be responsible for the impaired
NFAT-transcriptional response. Given that the effect of DYRK1A
appears not to be an on/off effect, the kinase could participate in
a mechanism regulating the amplitude or the duration of Ca2+
signaling and, hence, the activation of specific NFAT targets
(Kar and Parekh, 2015; Yissachar et al., 2013). VEGFR2 internal-
izes efficiently in serum-starved HUVECs independently of
ligand and upon VEGF stimulation (Basagiannis and Christofor-
idis, 2016). In addition, ligand-independent VEGFR2 ubiquitina-
tion has been linked to receptor membrane trafficking and
proteolysis (Smith et al., 2017). However, it is not clear whether
the constitutive VEGFR2 and the ligand-induced internaliza-
tion/degradation pathways share mechanisms and effectors.
We observed reduction of VEGFR2 in both serum-starved
HUVECs and upon VEGF treatment; however, we think that the
half-life measurements in VEGF-treated cells allow us to safely
propose that DYRK1A protects VEGFR2 from the internaliza-
tion-associated degradation of the receptor that follows ligand
binding. Currently, we cannot precisely define at which of the
steps that regulate VEGFR2 accumulation DYRK1A is acting: re-
ceptor internalization, intracellular trafficking, targeting to the
proteasome/lysosome degradation pathway, or recycling to
the membrane. However, the protective role of DYRK1A in
VEGFR2 homeostasis is quite comparable to that on EGF recep-
tor in adult neural stem cells or glioblastoma (Ferron et al., 2010;
Pozo et al., 2013) and could be an indication of a more general
role of DYRK1A on the regulation of RTK’s stability. Finally, we
are aware that given the pleiotropic nature of DYRK1A, our
data do not rule out other potential mechanisms, related or not
to the regulation of NFAT activity, that contribute to the participa-
tion of DYRK1A in angiogenesis.
In summary, our results are consistent with DYRK1A being
required for angiogenesis. Further in vivo analysis will be
necessary to fully elucidate the role of DYRK1A in physiological
angiogenesis and whether DYRK1A is important in pathological
conditions associated with angiogenesis, such as tumor-associ-
ated neovascularization and other angiogenesis-related dis-
eases. Such studies will surely provide valuable information on
the potential of using DYRK1A as a target for the therapeutic
manipulation of angiogenesis.
EXPERIMENTAL PROCEDURES
Cell Culture and Cell-Based Procedures
HUVECs were obtained from Lonza and maintained in EGM-2 BulletKit com-
plete Medium (Lonza). Cell treatments and extract preparation were done at
80% confluency. For growth curves, cells were plated at 4,000 cells/cm2 in
triplicate (day 0) and counted every 24 hr for 4 days. Transient DYRK1A
downregulation was achieved by small interfering RNA (siRNA) transfection
using Lipofectamine 3000. The siRNAs used were a control non-targeting
pool (D-001810-10) or a human DYRK1A SMARTpool (L-004805-00) ob-
tained from Dharmacon. Cell treatments were performed in basal EBM-2
medium (Lonza) supplemented with 2% fetal calf serum (FCS) (see Supple-
mental Experimental Procedures for conditions). See also Supplemental
Experimental Procedures for lentivirus stock preparation and infection and
conditions for 2D in vitro Matrigel assays. Intracellular Ca2+ was measured
as described previously (Jung et al., 2011). Mouse primary ECs were pre-1876 Cell Reports 23, 1867–1878, May 8, 2018pared from lungs of Dyrk1a+/ and wild-type littermates as described previ-
ously (Serra et al., 2015).
Animals
We used adult female Dyrk1a+/ mice (Fotaki et al., 2002) and their respective
wild-type littermates. The animals were maintained on their original genetic
background by repeated backcrossing of Dyrk1a+/ males to C57BL6/
Jx129S2/SvHsd F1 females (Harlan Laboratories); animals were genotyped
by PCR. All experimental procedures were carried out in accordance with Eu-
ropean Union guidelines (Directive 2010/63/EU). The protocols were approved
by the Ethics Committee of the CSIC and the IDIBELL.
Microarray Analysis and Quantification of mRNA
RNA samples for microarray analysis (three biological repeats of each sample)
were prepared from HUVECs according to the experimental conditions
indicated in Figure S1. A complete description of microarray processing and
analysis is provided in Supplemental Experimental Procedures. For mRNA
quantification, qPCR reactions were performed with SYBR green on cDNA
prepared from total RNA and specific oligonucleotides (sequences are pro-
vided in Table S1). Each sample was assayed in triplicate, and the threshold
cycle (Ct) was calculated using the Relative Quantification of the 2ndDerivative
Maximum method with Lightcycler 480 1.2 software (Roche). All results were
normalized to GAPDH or ACTB expression for HUVECs and Ppia for mouse
samples.
Protein Analysis
A complete description for western blot analysis and in vitro kinase assays is
provided in Supplemental Experimental Procedures. Antibody sources are
listed in Table S2. Immunofluorescence studies were performed as described
previously (Aranda et al., 2008; see also Supplemental Experimental Proced-
ures). Information on visualization and quantification of the retinal vasculature
is also included.
Statistics
The statistical package included in GraphPad Prism 6 was used. Normality of
sample data was evaluated with a D’Agostino and Pearson omnibus test. If
samples passed the normality test, a two-tailed unpaired Student’s t test
was used; if not, significant differences were defined in pairwise comparisons
using a two-tailed Mann-Whitney U test. For multiple comparisons, a one-way
ANOVA with Bonferroni corrections was used. The data in the graphs repre-
sent the mean ± SD of independent experiments. A p value < 0.05 was consid-
ered significant (*p < 0.05; **p < 0.001; ***p < 0.0001). All experiments were
performed independently at least three times.
Data and Software Accessibility
The accession number for the microarray data reported in this paper is GEO:
GSE112172.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
seven figures, and two tables and can be found with this article online at
https://doi.org/10.1016/j.celrep.2018.04.008.
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